Recherches "plusieurs pathologies" RAGNAR (42756493CAN2002) A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene;Alterations Paris CHRISTOPHE LE TOURNEAU
Sein métastatique RH+ SERENA-2 (D8530C00002) SERENA-2: A Randomised, Open-Label, Parallel-Group, Multicentre Phase;2 Study Comparing the Efficacy and Safety of Oral AZD9833 versus;Fulvestrant in Women with Advanced ER-Positive HER2-Negative Breast;Cancer Paris FRANCOIS-CLEMENT BIDARD
Pédiatrie Tumeurs solides CA045-020 (PIVOT IO 020) Phase 1/2 Study of Bempegaldesleukin in Combination with Nivolumab in Children,;Adolescents, and Young Adults with Recurrent or Refractory Malignancies (PIVOT IO 020) Paris FRANCOIS DOZ
Gynécologie - Ovaires AGO-OVAR 2.29 Atezolizumab in combination with Bevacizumab and Chemotherapy;versus Bevacizumab and Chemotherapy;in recurrent ovarian cancer À a randomized Phase III trial;An ENGOT Trial Paris MANUEL RODRIGUES
Sein métastatique RH+ ESTROTIMP Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer (ESTROTIMP) Paris, Saint-Cloud
Sein métastatique HER2+ BO25430 AN OPEN-LABEL, MULTICENTER EXTENSION STUDY OF TRASTUZUMAB EMTANSINE ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS PREVIOUSLY ENROLLED IN A GENENTECH AND/OR F. HOFFMANN-LA ROCHE LTD·SPONSORED TRASTUZUMAB EMTANSINE STUDY. Saint-Cloud FLORENCE LEREBOURS
Soins de support CINNAMON Evaluation of the quality of life induced by the anti-odor cinnamon dressing in patients with malodorous wounds: a multicenter randomized controlled trial. Paris
Sein métastatique RH+ CT7001_003 (SUMIT ELA) A Phase 1b/2 Open-label Study of Samuraciclib in Combination with Elacestrant in;Participants with Metastatic or Locally Advanced Hormone Receptor-positive and Human;Epidermal Growth Factor Receptor 2-negative Breast Cancer. Saint-Cloud FRANCOIS-CLEMENT BIDARD